New dystonic syndrome associated with butyrophenone therapy.
D000588:Amines; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001479:Basal Ganglia / Q000187:drug effects; D002090:Butyrophenones / Q000009:adverse effects* / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy; D005260:Female; D005684:Gait; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010640:Phenothiazines / Q000009:adverse effects; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011187:Posture
D000588:Amines; D000978:Antiparkinson Agents; D002090:Butyrophenones; D010640:Phenothiazines; D010880:Piperidines; D006220:Haloperidol